Click Therapeutics has acquired Better Therapeutics' assets, including AspyreRx, the first FDA-authorized prescription digital therapeutic for type 2 diabetes, and development candidates BT-002, BT-003, and BT-004 for hypertension, hyperlipidemia, and metabolic dysfunction-associated steatohepatitis (MASH), respectively.
Click plans to enhance AspyreRx for obesity treatment and integrate it with its AI-enabled platform as part of its obesity digital therapeutic, CT-181. CT-181 aims to improve outcomes when combined with anti-obesity and diabetes medications like GLP-1s. This acquisition accelerates Click's initiatives in obesity and cardiometabolic diseases, complementing its existing digital treatments in psychiatry, CNS, and pain disorders.
Click will leverage Better Therapeutics' intellectual property to fast-track development timelines and create a superior digital therapy for chronic weight management. The integrated digital therapeutic will combine AspyreRx's validated behavioral therapy with Click's advanced engagement technology and AI platform, improving clinical outcomes and enhancing patient experience. The acquisition also supports the development of digital therapeutics for hypertension, hyperlipidemia, and MASH, further strengthening Click's portfolio.
Click Therapeutics is a leader in developing FDA-regulated prescription digital treatments for various medical needs, including major depressive disorder, schizophrenia, opioid use disorder, and preventive migraine treatment. The company focuses on combining technical and scientific rigor with patient-centric design to deliver effective, engaging digital therapeutics.
Click here to read the original news story.